Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. [electronic resource]
Producer: 20130405Description: 1597-602 p. digitalISSN:- 1556-679X
- Adolescent
- Adult
- Antibodies, Bacterial -- blood
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antibodies, Viral -- blood
- Female
- Humans
- Influenza Vaccines -- immunology
- Influenza, Human -- immunology
- Interleukin-17 -- antagonists & inhibitors
- Male
- Meningococcal Infections -- immunology
- Meningococcal Vaccines -- immunology
- Middle Aged
- Neisseria meningitidis -- immunology
- Orthomyxoviridae -- immunology
- Th17 Cells -- immunology
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.